Research Article| Volume 49, ISSUE 1, PS16-S21, September 24, 2004

The effects of tibolone and oestrogen-based HT on breast cell proliferation and mammographic density


      Tibolone is a tissue-selective compound used for the treatment of climacteric symptoms and the prevention of osteoporosis in post-menopausal women. In this review some in vitro data and clinical studies indicating that the effects of tibolone on breast tissue are different from those seen with oestrogen-based hormone therapy (HT) are briefly discussed. From a clinical perspective, an increase in mammographic density and breast cell proliferation should be regarded as an unwanted side-effect of HT. Efforts should therefore be made to define treatment regimens for post-menopausal women that have minimal effects on the breast but still maintain the many advantages of HT. Data suggest that tibolone may be such an alternative.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33.

        • Santen R.J.
        • Pinkerton J.
        • McCartney C.
        • Petroni G.R.
        Risk of breast cancer with progestins in combination with estrogens as hormone replacement therapy.
        J. Clin. Endocrinol. Metab. 2001; 86: 16-23
        • Lehman C.D.
        • White E.
        • Peacock S.
        • Drucker M.J.
        • Urban N.
        Effect of age and breast density on screening mammograms with false-positive findings.
        AJR Am. J. Roentgenol. 1999; 173: 1651-1655
        • Söderqvist G.
        • Isaksson E.
        • von Schoultz B.
        • Carlström K.
        • Tani E.
        • Skoog L.
        Proliferation of breast epithelial cells in healthy women during the menstrual cycle.
        Am. J. Obstet. Gynecol. 1997; 176: 123-128
        • Söderqvist G.
        • von Schoultz B.
        • Tani E.
        • Skoog L.
        Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle.
        Am J. Obstet. Gynecol. 1993; 168: 874-879
        • Menard S.
        • Casalini P.
        • Agresti R.
        • Pilotti S.
        • Balsari A.
        Proliferation of breast carcinoma during menstrual phases.
        Lancet. 1998; 352: 148-149
        • Isaksson E.
        • von Schoultz E.
        • Odlind V.
        • et al.
        Effects of oral contraceptives on breast epithelial proliferation.
        Breast Cancer Res. Treat. 2001; 65: 163-169
        • Cline J.M.
        • Söderqvist G.
        • von Schoultz E.
        • Skoog L.
        • von Schoultz B.
        Effects of conjugated estrogens, medroxyprogesterone acetate and tamoxifen on the mammary glands of macaques.
        Breast Cancer Res. Treat. 1998; 48: 221-229
        • Hofseth L.J.
        • Raafat A.M.
        • Osuch J.R.
        • Pathak D.R.
        • Slomski C.A.
        • Haslam S.Z.
        Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
        J. Clin. Endocrinol. Metab. 1999; 84: 4559-4565
        • Kloosterboer H.J.
        Tibolone: a steroid with a tissue-selective mode of action.
        J. Steroid Biochem. Mol. Biol. 2001; 76: 231-238
        • Palacios S.
        Tibolone: what does tissue specific activity mean?.
        Maturitas. 2001; 37: 159-165
      2. Kloosterboer HJ. New mechanisms of action for tibolone in breast cancer. In: Neves-e-Castro M, Wren BG, editors. Menopause hormones and cancer. New York: Parthenon; 2003. p. 37–47.

        • Chetrite G.
        • Kloosterboer H.J.
        • Pasqualini J.R.
        Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells.
        Anticancer Res. 1997; 17: 135-140
        • Kloosterboer H.J.
        Tibolone: a steroid with a tissue-selective mode of action.
        J. Steroid Biochem. Mol. Biol. 2001; 76: 231-238
        • Gooyer de M.E.
        • Oppers-Tiemissen H.M.
        • Leysen D.
        • Verheul H.A.M.
        • Kloosterboer H.J.
        Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC–MS/MS.
        Steroids. 2003; 68: 235-243
        • Gompel A.
        • Kandouz M.
        • Siromachkova M.
        • et al.
        The effect of tibolone on proliferation.
        Gynecol. Endocrinol. 1997; 11: 77-79
        • Gompel A.
        • Chaouat M.
        • Jacob D.
        • Perrot J.-Y.
        • Kloosterboer H.J.
        • Rostene W.
        In vitro studies of tibolone in breast cells.
        Fertil. Steril. 2002; 78: 351-359
        • Sendaǧ F.
        • Terek M.C.
        • Öz_ener S.
        • Öztekin K.
        Mammographic density changes in postmenopausal women using tibolone therapy.
        Int. J. Gynecol. Obstet. 2001; 74: 63-64
        • Erel C.T.
        • Elter K.
        • Akman C.
        • et al.
        Mammographic changes in women receiving tibolone therapy.
        Fertil. Steril. 1998; 69: 870-875
        • Kutlu T.
        • Ficicioglu C.
        The mammographic breast density changes after one year of tibolone use.
        Climacteric. 2002; 5: 138-139
        • Valdivia I.
        • Ortega D.
        Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy.
        Clin. Drug Invest. 2000; 20: 101-107
        • Colacurci N.
        • Fornaro F.
        • de Franciscis P.
        • Palermo M.
        • del Vecchio E.
        Effects of different types of hormone replacement therapy on mammographic density.
        Maturitas. 2001; 40: 159-164
        • Christodoulakos G.E.
        • Lambrinoudaki I.V.
        • Vourtsi A.D.
        • Panoulis K.P.C.
        • Kelekis D.A.
        • Creatsas G.C.
        Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study.
        Menopause. 2002; 9: 110-116
      3. Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavı́n P. Effect of tibolone and continuous combined hormone replacement therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril, submitted for publication.

        • Ozdemir A.
        • Konus O.
        • Nas T.
        • Erbas G.
        • Cosar S.
        • Iskik S.
        Mammographic and ultrasonic study of changes in the breast related to HRT.
        Int. J. Gynecol. Obstet. 1999; 67: 23-32
        • Şendaǧ F.
        • Cosan Terek M.
        • Ozsener S.
        • et al.
        Mammographic density changes during different postmenopausal hormone replacement therapies.
        Fertil. Steril. 2001; 76: 445-450
        • Erel C.T.
        • Esen G.
        • Seyisoglu H.
        • et al.
        Mammographic density increase in women receiving different hormone replacement regimens.
        Maturitas. 2001; 40: 151-157
        • Lundström E.
        • Christow A.
        • Svane G.
        • et al.
        Effects of tibolone and a continuous combined HRT regimen on mammographic breast density.
        Am. J. Obstet. Gynecol. 2002; 186: 717-722
        • Conner P.
        • Christow A.
        • Kersemaekers W.
        • et al.
        A comparative study on breast cell proliferation during HRT effects of tibolone and continuous combined estrogen progestogen treatment.
        Climacteric. 2004; 7: 50-58